echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Good long-term benefits of low-dose corticosteroids in rheumatoid arthritis patients over 65 years

    ARD: Good long-term benefits of low-dose corticosteroids in rheumatoid arthritis patients over 65 years

    • Last Update: 2022-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background : Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) , but the balance of benefits and harms remains uncle.


    Background Background : Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) , but the balance of benefits and harms remains uncle.


    Methods : The GLORIA (low-dose glucocorticoid in rheumatoid arthritis) practical double-blind randomized trial compared 2 years of prednisolone ( 5 mg / day) with placebo in patients over 65 years of age with active R.


    Methods The GLORIA (low-dose glucocorticoid in rheumatoid arthritis) practical double-blind randomized trial compared 2 years of prednisolone ( 5 mg / day) with placebo in patients over 65 years of age with active R.


    RESULTS: A total of 451 patients with established RA with an average of 1 comorbidities, a mean age of 72 years, a disease duration of 11 years, and a DAS28 of 5 were randomly assigne.


    CONCLUSIONS: Additional low-dose prednisolone has long-term beneficial effects in older patients with established RA , with increased benefit in most patients with non-severe AEs ; this suggests a good balance of benefits and harm.


    Boers M, Hartman L, Opris-Belinski D For the GLORIA Trial consortium , et a.


    Boers M, Hartman L, Opris-Belinski D For the GLORIA Trial consortium , et a.
    Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA tri.
    Annals of the Rheumatic Diseases2022; 81: 925-93 , et al Annals of the Rheumatic Diseases81: Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.